Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2016, Vol. 45 Issue (1): 56-60    DOI: 10.3785/j.issn.1008-9292.2016.01.09
神经内分泌肿瘤专题     
促泌素蛋白的分布和功能
刘琴, 来茂德
浙江大学医学院基础医学院 浙江省蛋白质组学重点实验室, 浙江 杭州 310058
Location and functions of secretagogin protein
LIU Qin, LAI Maode
Key Laboratory of Disease Proteomics of Zhejiang Province, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China
全文: PDF(820 KB)  
摘要: 

促泌素(secretagogin)蛋白是由奥地利学者在胰岛β细胞中鉴定出来的一个新型的EF-手型钙结合蛋白。该蛋白为六聚体左旋蛋白,表达主要集中于神经内分泌轴和中枢神经系统。促泌素有着丰富的生物学功能。一定程度的钙离子浓度变化会导致促泌素的构象发生变化,从而可能导致细胞内的信号转导改变。从已有的初步研究推断,促泌素将来有可能作为一种工具来治疗应激反应,如精神疾病(抑郁症)、烧伤或创伤后应激障碍和疼痛导致的慢性应激反应。在阿尔茨海默病中,促泌素在海马中的表达可阻止阿尔茨海默病神经退行性病变。促泌素亦可作为疾病标志物。在神经内分泌肿瘤中,促泌素与经典神经内分泌标志物嗜铬素A、突触素、神经元特异性烯醇化酶等有很好的一致性,但其总体敏感性和特异性更高。此外,脑缺血性疾病引起神经损伤后,促泌素会释放到血清中,这表明促泌素可作为脑损伤的标志物。本文结合促泌素蛋白在各种神经内分泌肿瘤中的分布、功能以及在非肿瘤性病变如阿尔茨海默病中的作用,对促泌素蛋白的研究进展进行综述。
关键词 ： 钙结合蛋白质类/供应和分配,  癌,神经内分泌/病理学,  阿尔茨海默病/病理生理学,  综述    
Abstract：

Secretagogin (SCGN) is a novel member of EF-hand Ca2+-binding proteins, which was identified in islet β cells by Wagner. SCGN is a six EF-hand Ca2+-binding protein, primarily expressed on the neuroendocrine axis and the central nervous system. The protein has abundant biological functions. A certain concentration of calcium ion can lead to conformation change of SCGN, resulting in the change of intracellular signal transduction. Preliminary studies showed that SCGN would be used to treat stress reaction, such as mental illness (depression), burns or post-traumatic stress disorder and chronic stress reaction caused by pain. In Alzheimer's disease, the expression of SCGN in the hippocampus can boycott neurodegeneration. In neuroendocrine tumors, SCGN presents a good consistency with neuroendocrine markers such as CgA, Syn, and NSE, with a higher overall sensitivity and specificity. In addition, SCGN is released into serum after neural damage in cerebral ischemic diseases, suggesting that SCGN can be used as a marker for brain trauma. In this article, we review the recent research progress of secretagogin, focus on its distribution and functions in various tumorous diseases and non-tumorous diseases, such as Alzheimer's disease.
Key words： Calcium-binding proteins/supply &    distribution    Carcinoma, neuroendocrine/pathology    Alzheimer's disease/physiopathology    Review
收稿日期: 2015-12-20     
CLC:  R73  
基金资助:

浙江省科技计划项目(2012C13014-3)
通讯作者: 来茂德(1960-),男,教授,博士生导师,主要从事大肠癌的病理学研究;E-mail:lmd@zju.edu.cn;http://orcid.org/0000-0001-6830-9774     E-mail: lmd@zju.edu.cn
作者简介: 刘琴(1991-),女,硕士研究生,主要研究促泌素在结直肠癌发展及预后中的意义;E-mail:707257439@qq.com;http://orcid.org/0000-0003-1891-2078
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　

引用本文:

刘琴 等. 促泌素蛋白的分布和功能[J]. 浙江大学学报（医学版）, 2016, 45(1): 56-60.
LIU Qin, LAI Maode. Location and functions of secretagogin protein. Journal of ZheJiang University(Medical Science), 2016, 45(1): 56-60.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2016.01.09      或      http://www.zjujournals.com/xueshu/med/CN/Y2016/V45/I1/56

[1] WAGNER L, OLIYARNYK O, GARTNER W, et al. Cloning and expression of secretagogin, a novel neuroendocrine and pancreatic islet of Langerhans-specific Ca2+-binding protein[J]. J Biol Chem, 2000, 275(32):24740-24751.
[2] WAGNER L, TEMPL E, REINING G, et al. Culture of human insulinoma cells:development of a neuroendocrine tumor cell and human pancreatic islet cell-specific monoclonal antibody[J]. J Endocrinol, 1998, 156(3):469-476.
[3] ROGSTAM A, LINSE S, LINDQVIST A, et al. Binding of calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin[J]. Biochem J, 2007, 401(1):353-363.
[4] ZIERHUT B, DANEVA T, GARTNER W, et al. Setagin and secretagogin-R22:posttranscriptional modification products of the secretagogin gene[J]. Biochem Biophys Res Commun, 2005, 329(4):1193-1199.
[5] BERGGÅRD T, MIRON S, ONNERFJORD P, et al. Calbindin D28k exhibits properties characteristic of a Ca2+ sensor[J]. J Biol Chem, 2002, 277(19):16662-16672.
[6] DESIDERIO D M, ZHAN X. The human pituitary proteome:the characterization of differentially expressed proteins in an adenoma compared to a control[J]. Cell Mol Biol(Noisy-le-grand), 2003, 49(5):689-712.
[7] GARTNER W, LANG W, LEUTMETZER F, et al. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca2+-binding protein[J]. Cereb Cortex, 2001, 11(12):1161-1169.
[8] ADOLF K, WAGNER L, BERGH A, et al. Secretagogin is a new neuroendocrine marker in the human prostate[J]. Prostate, 2007, 67:472-484.
[9] LEE J Y, BYUN J Y, LEE S H. Proteomic analysis of normal human nasal mucosa:establishment of a two-dimensional electrophoresis reference map[J]. Clin Biochem, 2009, 42(7-8):692-700.
[10] MULDER J, ZILBERTER M, SPENCE L, et al. Secretagogin is a Ca2+-binding protein specifying subpopulations of telencephalic neurons[J]. Proc Natl Acad Sci U S A, 2009, 106(52):22492-22497.
[11] SHI T J, XIANG Q, ZHANG M D, et al. Secretagogin is expressed in sensory CGRP neurons and in spinal cord of mouse and complements other calcium-binding proteins, with a note on rat and human[J]. Mol Pain, 2012, 8:80.
[12] PUTHUSSERY T, GAYET-PRIMO J, TAYLOR W R. Localization of the calcium-binding protein secretagogin in cone bipolar cells of the mammalian retina[J]. J Comp Neurol, 2010, 518(4):513-525.
[13] MONTANER J, MENDIOROZ M, RIBÓ M, et al. A panel of biomarkers including caspase-3 and D-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department[J]. J Intern Med, 2011, 270(2):166-174.
[14] MONTANER J, PEREA-GAINZA M, DELGADO P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers[J]. Stroke, 2008, 39(8):2280-2287.
[15] LEWIT-BENTLEY A, RÉTY S. EF-hand calcium-binding proteins[J]. Curr Opin Struct Biol, 2000, 10(6):637-643.
[16] HOLMES K C. Muscle proteins——their actions and interactions[J]. Curr Opin Struct Biol, 1996, 6(6):781-789.
[17] BHATTACHARYA S, BUNICK C G, CHAZIN W J. Target selectivity in EF-hand calcium binding proteins[J]. Biochim Biophys Acta, 2004, 1742(1-3):69-79.
[18] BAUER M C, O'CONNELL D J, MAJ M, et al. Identification of a high-affinity network of secretagogin-binding proteins involved in vesicle secretion[J]. Mol Biosyst, 2011, 7(7):2196-2204.
[19] ALPAR A, ATTEMS J, MULDER J, et al. The renaissance of Ca2+-binding proteins in the nervous system:secretagogin takes center stage[J]. Cell Signal, 2012, 24(2):378-387.
[20] BAXTER J D, FORSHAM P H. Tissue effects of glucocorticoids[J]. Am J Med, 1972, 53(5):573-589.
[21] ROMANOV R A, ALPÁR A, ZHANG M D, et al. A secretagogin locus of the mammalian hypothalamus controls stress hormone release[J]. EMBO J, 2015, 34(1):36-54.
[22] ATTEMS J, ITTNER A, JELLINGER K, et al. Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice[J]. J Neural Transm(Vienna), 2011, 118(5):737-745.
[23] BRAAK H, ALAFUZOFF I, ARZBERGER T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry[J]. Acta Neuropathol, 2006, 112(4):389-404.
[24] 王文军, 张帆, 何雷,等. 促泌素在胃肠道神经内分泌肿瘤中的表达及其临床意义[J]. 中国组织化学与细胞化学杂志, 2012, 21(2):186-191. WANG Wenjun, ZHANG Fan, HE Lei, et al. Expression of significance of secretagogin in gastrointestinal neuroendocrine tumors[J]. Chinese Journal of Histochemistry and Cytochemistry, 2012, 21(2):186-191. (in Chinese)
[25] LAI M, LÜ B, XING X, et al. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A[J]. Virchows Arch, 2006, 449(4):402-409.
[26] XING X, LAI M, GARTNER W, et al. Identification of differentially expressed proteins in colorectal cancer by proteomics:down-regulation of secretagogin[J]. Proteomics, 2006, 6(9):2916-2923.
[27] BAI Y, SUN Y, PENG J, et al. Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494[J]. Oncotarget, 2014, 5(17):7760-7775.
[28] ILHAN A, NEZIRI D, MAJ M, et al. Expression of secretagogin in clear-cell renal cell carcinomas is associated with a high metastasis rate[J]. Hum Pathol, 2011, 42(5):641-648.
[1] 郑艳榕,张翔南,陈忠. Nix介导的线粒体自噬机制的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 92-96.
[2] 李文龙,瞿海斌. 近红外光谱应用于中药质量控制及生产过程监控的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 80-88.
[3] 高思倩,沈咏梅,耿福能,李艳华,高建青. 糖尿病溃疡动物模型的建立及相关治疗研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 97-105.
[4] 王颖,汪仪,陈忠. 中枢胆碱能系统与癫痫关系的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 15-21.
[5] 高思倩,沈咏梅,耿福能,李艳华,高建青. 颞叶癫痫与海马成体神经再生[J]. 浙江大学学报（医学版）, 2017, 46(1): 97-105.
[6] 李统宇 等. 杜氏肌营养不良疾病模型及基因治疗研究进展[J]. 浙江大学学报（医学版）, 2016, 45(6): 648-654.
[7] 封盛 等. 糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展[J]. 浙江大学学报（医学版）, 2016, 45(6): 655-660.
[8] 曹鹏 等. 双氢青蒿素抗肿瘤分子生物学机制研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 501-507.
[9] 李亭亭 等. 中性粒细胞在哮喘中作用的研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 544-549.
[10] 王雪 等. TANK结合激酶1在抗病毒免疫应答中的作用研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 550-557.
[11] 何斌 等. 贝伐珠单克隆抗体在难治性子宫颈癌中的应用进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 395-402.
[12] 历雪莹 等. DNA甲基化及其靶向治疗在急性髓系白血病中的研究进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 387-394.
[13] 竺天虹 等. 上皮间充质转化介导子宫内膜异位症发生发展的研究进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 439-445.
[14] 杜苗苗 等. 钙化性主动脉瓣疾病药物治疗研究进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 432-438.
[15] 沈银忠 等. 人类免疫缺陷病毒暴露前预防的应用与挑战[J]. 浙江大学学报（医学版）, 2016, 45(3): 221-227.